Pascal Desroches to Update Shareholders at the 2025 Mizuho Technology Conference on June 10
Tomorrow, AT&T's chief financial officer will participate in a fireside chat where he will discuss the Company's multi-year strategic growth plan.
Key Takeaways:
AT&T reiterates full-year 2025 financial and operational guidance.
AT&T is pursuing a multi-year strategic growth plan that centers around putting customers first, continued network investment and increased capital returns to shareholders.
Pascal Desroches, chief financial officer, AT&T Inc. (NYSE: T), will speak tomorrow at the 2025 Mizuho Technology Conference where he will provide an update to shareholders.
AT&T continues to make progress on becoming the best connectivity provider in America
The Company continues to execute on its multi-year growth plan and differentiate its position within the connectivity industry by increasing its opportunity to serve customers how they want to be served, by one provider with fiber and 5G in a converged manner.
The Company recently announced an agreement to acquire substantially all of Lumen's Mass Markets fiber internet connectivity business. The transaction, which is expected to close in the first half of 2026, will expand investment in critical U.S. connectivity infrastructure, create new middle-class jobs and accelerate high-speed fiber internet access to millions of Americans.
Additionally, this deal will enable AT&T to significantly expand access to AT&T Fiber in new major metro areas and allow the Company to serve more customers with 5G and fiber together. AT&T continues to extend its fiber leadership with plans to reach approximately 60 million total fiber locations by year-end 2030. 1
Ultimately, this transaction aligns with the priorities outlined at AT&T's 2024 Analyst & Investor Day, including its goal of becoming the best connectivity provider in America while providing more value to customers, shareholders and the Company.
AT&T is seeing solid customer demand and remains on track to achieve its 2025 financial and operational guidance
The wireless industry remains both healthy and competitive, and the Company is pleased with how the Mobility business is performing in the second quarter.
In Consumer Wireline, the Company continues to expand access to AT&T Fiber – America's fastest internet with the most reliable speeds. 2 Trends in AT&T Fiber penetration rates remain consistent, with net adds varying from quarter to quarter based primarily on the pace of new fiber locations passed, seasonality and marketplace dynamics.
For the second-quarter 2025, the Company continues to expect capital investment* in the $4.5 billion to $5 billion range and free cash flow* of approximately $4 billion.
AT&T reiterates all full-year 2025 financial and operational guidance. Additionally, the Company continues to operate the business to achieve the financial plan and capital returns outlined at its 2024 Analyst & Investor Day.
AT&T remains committed to repurchasing shares under the previously announced $10 billion authorization, with plans to repurchase at least $3 billion of common stock by year-end and the remainder during 2026.
Conference details and more are available on the AT&T Investor Relations website
Full conference details are posted on the AT&T Investor Relations website, including a replay of the webcast.
To automatically receive AT&T financial news by email, please subscribe to email alerts.
1 "Total locations" includes consumer and business locations (i) passed with fiber and (ii) served with fiber through commercial open-access providers.
2 Limited availability in select areas. Based on analysis by Ookla® of Speedtest Intelligence® data nationwide Speed Score and Consistency Score for Q3–Q4 2024. Ookla trademarks used under license and reprinted with permission.
*Due to high variability and difficulty in predicting items that impact cash from operating activities, capital expenditures and vendor financing payments, the Company is not able to provide a reconciliation between second quarter 2025 projected capital investment or free cash flow and the most comparable GAAP metrics without unreasonable effort.
Cautionary Language Concerning Forward-Looking Statements
Information set forth in this news release contains financial estimates and other forward-looking statements that are subject to risks and uncertainties, and actual results might differ materially. A discussion of factors that may affect future results is contained in AT&T's filings with the Securities and Exchange Commission. AT&T disclaims any obligation to update and revise statements contained in this news release based on new information or otherwise. This news release may contain certain non-GAAP financial measures. Reconciliations between the non-GAAP financial measures and the GAAP financial measures are available on the company's website at investors.att.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
9 hours ago
- Globe and Mail
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
15 hours ago
- Globe and Mail
1 Brilliant Quantum Computing Stock to Buy Before It Soars 70%, According to 1 Wall Street Analyst
Key Points IonQ is taking a unique approach to quantum computing. Quantum computing is expected to reach a turning point around 2030. 10 stocks we like better than IonQ › Wall Street analysts often give one-year price targets for stocks as a guide to where they think the stock is heading. While these projections are inherently flawed and in no way guarantee what will happen to a stock, understanding what the general analyst community thinks about a stock can be helpful in shaping your own research, especially in an area like quantum computing where there's a lot of hype. Kevin Garrigan from Rosenblatt Security recently set a new price target for quantum computing pure play IonQ (NYSE: IONQ). As of Wednesday's market close, IonQ was trading at $41.21 per share. Garrigan's price target is $70, indicating about 70% upside. That's a strong return in a short time frame, but is IonQ stock a buy now? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » IonQ's trapped ion approach shows potential IonQ is a leading quantum computing company, which is impressive considering that it doesn't have another business to fund its operations. IonQ relies on raising capital in the public markets and various contracts it has to fund its research, unlike many of the big tech competitors in this space, which have massive cash flows to fund their quantum computing research. Despite this disadvantage, IonQ has developed impressive quantum computing technology. IonQ has taken the trapped ion approach to quantum computing, which has benefits and drawbacks. On the plus side, trapped ion architecture has impressive fidelity, and IonQ holds the world record in 1-qubit gate fidelity tests. (A qbit, or quantum bit, is the basic unit of information used in quantum computing to encode data.) It can also be done at room temperature, while other solutions need to be cooled to absolute zero. On the downside, trapped ion quantum computing can have a slightly slower processing speed compared to other solutions. Time will tell whether this is a winning approach, but some of IonQ's early successes indicate that it could be viable. But will that be enough to deliver the $70 stock price that Garrigan thinks is possible? IonQ won't see real business gains for at least a few years Any stock price prediction for IonQ is speculation. While it has a handful of contracts and its quantum computing devices are available for use on all three major cloud computing services, there's really no commercial market for quantum computing right now. However, most quantum computing companies point toward 2030 being a key year, and IonQ is no exception. Its CEO projected that IonQ would be profitable and generate sales of nearly $1 billion by 2030. After that, management expects significant market expansion, with an $87 billion market emerging by 2035. To bridge the gap between profitability and its research phase, IonQ has $1.6 billion in cash, cash equivalents, and outside investments, which should allow it to reach this critical point. While it's impossible to know if IonQ's technology will propel it to be a winning quantum computing pick over the next few years, investors can feel confident that IonQ has the proper resources and backing to at least get to that point. Whether that's worth a $70-per-share target is a different question that I can't answer, but with all of the momentum behind quantum computing, I have a hard time seeing this stock slowing down anytime soon. As a result, I think it's worth an investment, as long as the position size is kept relatively small to help manage risk. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
16 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
